ClinVar Miner

Submissions for variant NM_023036.6(DNAI2):c.1304G>A (p.Trp435Ter)

gnomAD frequency: 0.00008  dbSNP: rs752924362
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000220262 SCV000271356 pathogenic Primary ciliary dyskinesia 2015-09-03 criteria provided, single submitter clinical testing The p.Trp435X variant in DNAI2 has been reported in 3 Ashkenazi Jewish individua ls with PCD, all of whom were homozygous for the variant, and in 2 Caucasian sib lings with PCD, both of whom were compound heterozygous with a second pathogenic DNAI2 variant (Knowles 2013, Zariwala 2013). This variant has been identified i n 14/66582 European chromosomes by the Exome Aggregation Consortium (ExAC, http: //exac.broadinstitute.org; dbSNP rs752924362). Please note that presence in the general population does not contradict pathogenicity, especially for recessive d isorders and disorders with reduced penetrance. This nonsense variant leads to a premature termination codon at position 435, which is predicted to lead to a tr uncated or absent protein. In summary, this variant meets our criteria to be cla ssified as pathogenic for PCD in an autosomal recessive manner (http://www.partn ers.org/personalizedmedicine/LMM) based on multiple reports of this variant in i ndividuals with PCD and the predicted impact of the variant.
Counsyl RCV000410372 SCV000487055 pathogenic Primary ciliary dyskinesia 9 2016-10-18 criteria provided, single submitter clinical testing
Invitae RCV000220262 SCV000624446 pathogenic Primary ciliary dyskinesia 2024-01-24 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Trp435*) in the DNAI2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DNAI2 are known to be pathogenic (PMID: 18950741, 23891469). This variant is present in population databases (rs752924362, gnomAD 0.3%). This premature translational stop signal has been observed in individuals with primary ciliary dyskinesia (PMID: 23261302, 23891469). ClinVar contains an entry for this variant (Variation ID: 228335). For these reasons, this variant has been classified as Pathogenic.
Illumina Laboratory Services, Illumina RCV000410372 SCV000914791 likely pathogenic Primary ciliary dyskinesia 9 2018-12-04 criteria provided, single submitter clinical testing The DNAI2 c.1304G>A (p.Trp435Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. The p.Trp435Ter variant has been reported in one study and found in three individuals with primary ciliary dyskinesia, all in a homozygous state (Knowles et al. 2013). Control data are unavailable for this variant, which is reported at a frequency of 0.003376 in the Ashkenazi Jewish population of the Genome Aggregation Database. It is suggested that this variant may be a founder variant in the Ashkenazi Jewish population (Knowles et al. 2013; Fedick et al. 2015). Based on the potential impact of stop-gained variants and the clinical evidence, the p.Trp435Ter variant is classified as likely pathogenic for primary ciliary dyskinesia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Fulgent Genetics, Fulgent Genetics RCV000410372 SCV002782505 pathogenic Primary ciliary dyskinesia 9 2022-02-25 criteria provided, single submitter clinical testing
Ambry Genetics RCV000220262 SCV003992300 pathogenic Primary ciliary dyskinesia 2023-05-30 criteria provided, single submitter clinical testing The p.W435* pathogenic mutation (also known as c.1304G>A), located in coding exon 9 of the DNAI2 gene, results from a G to A substitution at nucleotide position 1304. This changes the amino acid from a tryptophan to a stop codon within coding exon 9. This variant was identified in several individuals in the homozygous and compound heterozygous state with a clinical diagnosis or high clinical suspicion of primary ciliary dyskinesia (Zariwala MA et al. Am J Hum Genet, 2013 Aug;93:336-45; Knowles MR et al. Am J Hum Genet, 2013 Jan;92:99-106; Shoemark A et al. Eur Respir J, 2022 Nov;60:). It was also identified in the homozygous state in an individual with bronchiectasis (Gileles-Hillel A et al. ERJ Open Res, 2020 Oct;6:). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Revvity Omics, Revvity Omics RCV000410372 SCV004234746 pathogenic Primary ciliary dyskinesia 9 2023-02-09 criteria provided, single submitter clinical testing
OMIM RCV000410372 SCV000056626 pathogenic Primary ciliary dyskinesia 9 2013-01-10 no assertion criteria provided literature only
Natera, Inc. RCV000220262 SCV001459509 pathogenic Primary ciliary dyskinesia 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.